Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo
European Journal of Cancer · 2025-01 · 214 · 115141
DOI: 10.1016/j.ejca.2024.115141 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift European Journal of Cancer, 2025-01. Verfasst von Irene L M Reijers und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Melanoma, Neoadjuvant Therapy, Neoplasm Staging, Ipilimumab. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Bristol-Myers Squibb Company.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
- Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Department of Medical Oncology, Royal North Shore and…
- Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands.
- Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Department of Melanoma and Surgical Oncology, Royal Pr…
- Department of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
- Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands.
Förderung
- Bristol-Myers Squibb Company
Zitieren
APA
Reijers, I. L. M., Menzies, A. M., Lopez-Yurda, M., Versluis, J. M., Rozeman, E. A., Saw, R. P. M., van Houdt, W. J., Kapiteijn, E., van der Veldt, A. A. M., Suijkerbuijk, K. P. M., Eriksson, H., Hospers, G. A. P., Klop, W. M. C., Torres Acosta, A., Grijpink-Ongering, L., Gonzalez, M., van der Wal, A., Al-Mamgani, A., Spillane, A. J., …, & Blank, C. U. (2025). Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo. European Journal of Cancer, 214, 115141. https://doi.org/10.1016/j.ejca.2024.115141
Vancouver
Reijers ILM, Menzies AM, Lopez-Yurda M, Versluis JM, Rozeman EA, Saw RPM, et al. Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo. European Journal of Cancer. 2025;214:115141. doi:10.1016/j.ejca.2024.115141
BibTeX
@article{Reijers2025,
author = {Reijers, Irene L M and Menzies, Alexander M and Lopez-Yurda, Marta and Versluis, Judith M and Rozeman, Elisa A and Saw, Robyn P M and van Houdt, Winan J and Kapiteijn, Ellen and van der Veldt, Astrid A M and Suijkerbuijk, Karijn P M and Eriksson, Hanna and Hospers, Geke A P and Klop, Willem M C and Torres Acosta, Alejandro and Grijpink-Ongering, Lindsay and Gonzalez, Maria and van der Wal, Anja and Al-Mamgani, Abrahim and Spillane, Andrew J and Scolyer, Richard A and van de Wiel, Bart A and van Akkooi, Alexander C J and Long, Georgina V and Blank, Christian U},
title = {Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo},
journal = {European Journal of Cancer},
year = {2025},
volume = {214},
pages = {115141},
doi = {10.1016/j.ejca.2024.115141}
}
EUVIMED